Conference Addresses MENA Biologics Growth at CPhI Istanbul 2017

Article

Local manufacturing, regulatory strategies, market entry, and harmonization to be featured at CPhI Istanbul.

CPhI Istanbul, organized by UBM EMEA in partnership with Pharmaceutical Manufacturers Association of Turkey, returns to Turkey for its fourth edition with a new co-located event and a new venue. Scheduled for March 8-10, 2017, the five-in-one event-ICSE, CPhI, P-MEC, Innopack, and the new BioPh-is expected to bring together over 4500 pharma industry leaders from 82 countries and 236 exhibitors, organizers report.

For 2017, the event will be held in a new venue, the Istanbul Expo Centre (IFM), to accommodate a 72% increase in floor space and exhibitors since its inauguration.

The event organizers cite a rapidly emerging MENA biologics industry in Turkey and the wider region as a factor in the need for a biopharma conference. The Turkish government has initiated measures to stimulate expansion of biotechnology and biopharmaceutical activities, including incentive to cover up to half of expenditures related to biopharm R&D.

The Biopharma conference at CPhI Istanbul, backed by the local and national government, will feature three days of sessions where 300 speakers and delegates discuss the opportunities for companies in Turkey and the MENA region. The conference includes educational and analytical sessions on IP security, regulatory procedures, and market strategies; the future of biosimilars, clinical trials, and R&D. The conference includes in-depth analysis on local guidelines, incentives, and government funding in Turkey; the future of biosimilars and biobetters; regional and global outlook and sales forecasts; and case studies and business models.

Roundtable discussions will address drug registration processes, marketing channels, pricing and reimbursement, and business culture and economic outlook.

Other special events include a C-suite Meet-up, a matchmaking program, a women’s networking event, and exhibitor seminars.

CPhI Istanbul is part of the Hosted Buyer Programme of the Turkish Ministry of Economy, which enables costs of eligible clients to be covered by the Ministry. The event is supported by the Turkish Ministry of Health, Turkish Ministry of Economy and the Presidency of Administration of Small and Medium Sized Industrial Enterprises (KOSGEB).

Editor’s Note: CPhI and Pharmaceutical Technology are UBM plc brands.

Source: CPhI Instanbul

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content